688336 三生国健
午间休市 07-30 11:29:58
资讯
新帖
简况
单抗概念盘中拉升,恒瑞医药涨8.69%
市场透视 · 07-28 03:06
单抗概念盘中拉升,恒瑞医药涨8.69%
三生国健:8月11日将召开2025年第四次临时股东大会
证券日报网 · 07-24
三生国健:8月11日将召开2025年第四次临时股东大会
上海板块盘中拉升,仁度生物涨14.77%
市场透视 · 07-24
上海板块盘中拉升,仁度生物涨14.77%
生物制品行业盘中拉升,智飞生物涨14.73%
市场透视 · 07-24
生物制品行业盘中拉升,智飞生物涨14.73%
三生国健股价下跌4.89% 与辉瑞达成超60亿美元授权交易
金融界 · 07-22
三生国健股价下跌4.89% 与辉瑞达成超60亿美元授权交易
挑战全球自免“药王”!中国创新药企想杀出一条血路
健识局 · 07-16
挑战全球自免“药王”!中国创新药企想杀出一条血路
麦济生物冲击港股IPO:核心在研产品赛道拥挤,曾被判专利侵权三生国健
蓝鲸财经 · 07-16
麦济生物冲击港股IPO:核心在研产品赛道拥挤,曾被判专利侵权三生国健
三生国健下跌5.11% 资金博弈加剧叠加估值修正需求
智选洞察 · 07-14
三生国健下跌5.11% 资金博弈加剧叠加估值修正需求
每周股票复盘:三生国健(688336)召开2025年第三次临时股东大会审议通过外汇套期保值议案
证券之星 · 07-12
每周股票复盘:三生国健(688336)召开2025年第三次临时股东大会审议通过外汇套期保值议案
三生国健涨5.03% 创新突破与业绩验证驱动股价上行
智选洞察 · 07-11
三生国健涨5.03% 创新突破与业绩验证驱动股价上行
2025上半年BD王者榜:国产创新药的国际突围
CPHI制药在线 · 07-09
2025上半年BD王者榜:国产创新药的国际突围
三生国健主力两日净流出6171.5万 短期股价或承压
智选洞察 · 07-08
三生国健主力两日净流出6171.5万 短期股价或承压
被牛市遗忘的CXO,谁将凭“拐点基因”破局
动脉网 · 07-08
被牛市遗忘的CXO,谁将凭“拐点基因”破局
7月7日三生国健跌5.20%,交银医药创新股票A基金重仓该股
证券之星 · 07-07
7月7日三生国健跌5.20%,交银医药创新股票A基金重仓该股
三生国健股价下跌5.00% 创近三个月新低 资金博弈与估值修正共振
智选洞察 · 07-07
三生国健股价下跌5.00% 创近三个月新低 资金博弈与估值修正共振
生物制品行业盘中拉升,荣昌生物涨8.21%
市场透视 · 07-01
生物制品行业盘中拉升,荣昌生物涨8.21%
市场规模将增至108亿!国内一批药企在痛风药物领域展开激烈角逐
制药网 · 07-01
市场规模将增至108亿!国内一批药企在痛风药物领域展开激烈角逐
中国创新药能否持续让世界买单?券商分析师最新观点
券商中国 · 06-30
中国创新药能否持续让世界买单?券商分析师最新观点
三生国健06月26日遭主力抛售6530.1万元
市场透视 · 06-26
三生国健06月26日遭主力抛售6530.1万元
三生国健:向激励对象授予115.70万股限制性股票
格隆汇资讯 · 06-25
三生国健:向激励对象授予115.70万股限制性股票
加载更多
公司概况
公司名称:
三生国健药业(上海)股份有限公司
所属行业:
医药制造业
上市日期:
2020-07-22
主营业务:
三生国健药业(上海)股份有限公司的主营业务是抗体药物的研发、生产和销售。公司的主要产品是益赛普、赛普汀、健尼哌。公司是“免疫与炎症全国重点实验室”依托单位、拥有抗体药物国家工程研究中心、国家企业技术中心、上海市抗体技术创新中心、上海抗体工程技术研究中心等国家级和上海市级高新技术平台,承担过国家重大新药创制、“863”计划、国家发改委及上海市重大项目及各部委课题百余项,多次获得上海市级和浦东新区科学技术奖。
发行价格:
28.18
{"stockData":{"symbol":"688336","market":"SH","secType":"STK","nameCN":"三生国健","latestPrice":54.88,"timestamp":1753846198000,"preClose":56,"halted":0,"volume":4114428,"delay":0,"changeRate":-0.02,"floatShares":617000000,"shares":617000000,"eps":1.1616,"marketStatus":"午间休市","change":-1.12,"latestTime":"07-30 11:29:58","open":55.18,"high":56.33,"low":54.68,"amount":228000000,"amplitude":0.0295,"askPrice":54.94,"askSize":67,"bidPrice":54.89,"bidSize":8,"shortable":0,"etf":0,"ttmEps":1.1616,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753851600000},"marketStatusCode":3,"adr":0,"adjPreClose":56,"symbolType":"stock_kcb","openAndCloseTimeList":[[1753839000000,1753846200000],[1753851600000,1753858800000]],"highLimit":61.6,"lowLimit":50.4,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":616785793,"isCdr":false,"pbRate":6.09,"roa":"--","peRate":47.245179,"roe":"1.83%","epsLYR":1.14,"committee":-0.223684,"marketValue":33849000000,"turnoverRate":0.0067,"status":1,"floatMarketCap":33849000000},"requestUrl":"/m/hq/s/688336","defaultTab":"news","newsList":[{"id":"2554574758","title":"单抗概念盘中拉升,恒瑞医药涨8.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2554574758","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554574758?lang=zh_cn&edition=full","pubTime":"2025-07-28 11:06","pubTimestamp":1753672018,"startTime":"0","endTime":"0","summary":"07月28日,单抗概念盘中拉升,截至11点06分,单抗概念整体指数上涨1.00%,报2685.600点。从个股上来看,该概念的成分股中,恒瑞医药涨8.69%,君实生物-U、泽璟制药-U、三生国健涨幅居前。从资金上来看,截止发稿,单抗概念概念主力净流入为2.59亿,其中恒瑞医药受到资金热捧,主力净流入5.73亿;拉长时间线来看,该板块近20日主力资金净流入-14.56亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072811065897224c2f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072811065897224c2f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0405327494.USD","BK0060","LU1997245177.USD","688180","LU0405327148.USD","LU1328615791.USD","BK0239","BK0196","LU1969619763.USD","LU1064131003.USD","LU2495084118.USD","LU2148510915.USD","BK0028","LU2488822045.USD","600276","LU2328871848.SGD","688336","BK0012","688266","BK0188","LU1655091616.SGD","LU1064130708.USD","01276","LU1997245094.SGD","BK0183","LU1997244956.HKD"],"gpt_icon":0},{"id":"2553789970","title":"三生国健:8月11日将召开2025年第四次临时股东大会","url":"https://stock-news.laohu8.com/highlight/detail?id=2553789970","media":"证券日报网","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553789970?lang=zh_cn&edition=full","pubTime":"2025-07-24 22:09","pubTimestamp":1753366140,"startTime":"0","endTime":"0","summary":"证券日报网讯7月24日晚间,三生国健发布公告称,公司将于2025年8月11日召开2025年第四次临时股东大会。本次股东大会将审议《关于与关联方共同签署<许可协议之补充协议二>的议案》。\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-07-24/doc-infhqxsm2485748.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-07-24/doc-infhqxsm2485748.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688336"],"gpt_icon":0},{"id":"2553279724","title":"上海板块盘中拉升,仁度生物涨14.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553279724","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553279724?lang=zh_cn&edition=full","pubTime":"2025-07-24 14:33","pubTimestamp":1753338818,"startTime":"0","endTime":"0","summary":"07月24日,上海板块盘中拉升,截至14点33分,上海板块整体指数上涨1.01%,报2951.280点。从个股上来看,该板块的成分股中,仁度生物涨14.77%,中颖电子涨幅超过10%,三生国健、司南导航等8只股涨幅超过5%。从资金上来看,截止发稿,上海板块主力净流入为2.66亿,其中东方财富受到资金热捧,主力净流入11.04亿;拉长时间线来看,该板块近20日主力资金净流入-386.29亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072414333894b7aa3a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072414333894b7aa3a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688592","688193","BK0239","688336"],"gpt_icon":0},{"id":"2553275996","title":"生物制品行业盘中拉升,智飞生物涨14.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553275996","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553275996?lang=zh_cn&edition=full","pubTime":"2025-07-24 13:14","pubTimestamp":1753334051,"startTime":"0","endTime":"0","summary":"07月24日,生物制品行业盘中拉升,截至13点14分,生物制品行业整体指数上涨3.01%,报6791.950点。从个股上来看,该行业的成分股中,智飞生物涨14.73%,沃森生物、三生国健2只个股涨幅超过10%,康泰生物、康希诺等3只股涨幅超过5%。从资金上来看,截止发稿,生物制品行业主力净流入为6326.04万,其中智飞生物受到资金热捧,主力净流入1.79亿;拉长时间线来看,该板块近20日主力资金净流入-27.46亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724131411971b466a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724131411971b466a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688336","LU1064131003.USD","BK0077","BK0239","LU2580892862.HKD","BK0196","LU2580892789.USD","300122","BK0046","LU1328615791.USD","BK0188","LU2148510915.USD","LU1064130708.USD","688185"],"gpt_icon":0},{"id":"2553268816","title":"三生国健股价下跌4.89% 与辉瑞达成超60亿美元授权交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2553268816","media":"金融界","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553268816?lang=zh_cn&edition=full","pubTime":"2025-07-23 02:26","pubTimestamp":1753208798,"startTime":"0","endTime":"0","summary":"截至2025年7月22日收盘,三生国健股价报54.44元,较前一交易日下跌4.89%,成交额4.91亿元。三生国健是一家专注于生物医药研发的企业,主要涉及生物制品、重组蛋白及单抗药物等领域。消息面上,三生国健近期与跨国药企辉瑞达成一项重磅授权交易,涉及PD-1/VEGF双抗药物SSGJ-707的海外权益。根据协议,三生国健及其关联公司获得的首付款达12.5亿美元,总交易金额超过60亿美元,创下国产创新药出海首付款纪录。资金方面,7月22日主力资金净流出4840.44万元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/07/23022651905540.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["IE00BLSP4452.SGD","LU0122379950.USD","LU1023059063.AUD","BK4581","LU0321505439.SGD","688336","BK4550","LU1894683348.USD","LU0289739699.SGD","BK0239","PFE","LU0306806265.USD","IE0002270589.USD","LU1057294990.SGD","LU0170899867.USD","IE00BLSP4239.USD","LU1066053197.SGD","BK4533","LU0868494617.USD","BK4588","BK4007","LU0225284248.USD","BK4585","BK4534","BK4592","BK4599","LU1883839398.USD","LU0456855351.SGD","BK4568","SG9999002224.SGD","LU0225771236.USD","SG9999001176.USD","SG9999002232.USD","IE00B19Z3B42.SGD","IE00B19Z3581.USD","IE000M9KFDE8.USD","LU0321505868.SGD","SG9999001176.SGD","LU0058720904.USD","LU0985481810.HKD","SG9999013999.USD","SGXZ57979304.SGD","LU0306807586.USD","SG9999003800.SGD","LU1894683264.USD","SG9999011175.SGD","LU1066051498.USD","IE00BBT3K403.USD","LU0234572021.USD"],"gpt_icon":0},{"id":"2551945123","title":"挑战全球自免“药王”!中国创新药企想杀出一条血路","url":"https://stock-news.laohu8.com/highlight/detail?id=2551945123","media":"健识局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551945123?lang=zh_cn&edition=full","pubTime":"2025-07-16 20:40","pubTimestamp":1752669633,"startTime":"0","endTime":"0","summary":"自免药王度普利尤单抗的挑战者又添一位。麦济生物创立于2016年,是一家做自免药物研发的创新药企,核心药物MG-K10是IL-4单抗,用于中重度成人的特应性皮炎。2024年,度普利尤单抗依靠142亿美元的销售额,成为了自免销冠,一举超越了前“药王”修美乐。2020年4月,上海知识产权法院出具了民事判决书,将这项专利划归三生国健所有。而它最强力的对手,就是全球的自免“药王”度普利尤单抗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716204457a6ad8a27&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716204457a6ad8a27&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159992","688336","BK0239"],"gpt_icon":0},{"id":"2551145950","title":"麦济生物冲击港股IPO:核心在研产品赛道拥挤,曾被判专利侵权三生国健","url":"https://stock-news.laohu8.com/highlight/detail?id=2551145950","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551145950?lang=zh_cn&edition=full","pubTime":"2025-07-16 16:26","pubTimestamp":1752654414,"startTime":"0","endTime":"0","summary":"不过,值得注意的是,麦济生物曾就IL-4Rα相关专利与科创板上市公司三生国健有过一起诉讼纠纷。此外,麦济公司并未提供涉案专利申请技术研发的任何实验数据。不过,麦济生物并未在MG-K10产品的核心专利中列入上述侵权的专利。2016年至2025年,麦济生物完成了多轮融资和股权转让。张成海及麦康克将被视为一组控股股东。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716162744954499b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716162744954499b0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00867","BK0239","688336"],"gpt_icon":0},{"id":"2551292700","title":"三生国健下跌5.11% 资金博弈加剧叠加估值修正需求","url":"https://stock-news.laohu8.com/highlight/detail?id=2551292700","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551292700?lang=zh_cn&edition=full","pubTime":"2025-07-14 09:39","pubTimestamp":1752457189,"startTime":"0","endTime":"0","summary":"三生国健股价大幅下跌,最新价53.28元,跌幅达5.11%。资金博弈与政策预期共振三生国健近期股价波动与资金高频切换密切相关。生物制品板块受上证指数6月25日单日下跌0.70%影响,部分资金选择兑现年内超150%涨幅,叠加半年末机构调仓窗口,资金转向防御性资产。此外,动态市盈率45.87倍仍高于行业中枢,技术面压力与估值修正需求形成共振,量比波动显示多空分歧延续。创新兑现与业绩韧性双线验证长期来看,三生国健价值锚定于创新药商业化进程。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714093959a448a537&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714093959a448a537&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688336","BK0239"],"gpt_icon":0},{"id":"2551157499","title":"每周股票复盘:三生国健(688336)召开2025年第三次临时股东大会审议通过外汇套期保值议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2551157499","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551157499?lang=zh_cn&edition=full","pubTime":"2025-07-13 01:42","pubTimestamp":1752342130,"startTime":"0","endTime":"0","summary":"截至2025年7月11日收盘,三生国健报收于56.15元,较上周的55.38元上涨1.39%。本周,三生国健7月11日盘中最高价报56.3元。本周关注点公司公告汇总:三生国健召开2025年第三次临时股东大会,审议通过《关于2025年度开展外汇套期保值业务的议案》公司公告汇总三生国健药业(上海)股份有限公司2025年第三次临时股东大会于2025年7月11日在上海召开。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071300000181.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"gpt_icon":0},{"id":"2550098882","title":"三生国健涨5.03% 创新突破与业绩验证驱动股价上行","url":"https://stock-news.laohu8.com/highlight/detail?id=2550098882","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550098882?lang=zh_cn&edition=full","pubTime":"2025-07-11 13:06","pubTimestamp":1752210398,"startTime":"0","endTime":"0","summary":"三生国健股价大幅上涨,最新价55.34元/股,涨幅达5.03%。资金博弈与估值修正共振三生国健近期股价波动与主力资金高频切换密切相关。创新突破与业绩验证双轮驱动三生国健长期价值锚定于核心业务突破,2024年医药制造收入占比83.02%,CDMO业务增速居行业前列。5月27日龙虎榜显示两家机构合计买入4447万元,反映专业投资者对创新药管线的认可。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711130650a6a2f7ce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711130650a6a2f7ce&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688336","BK0239"],"gpt_icon":0},{"id":"2550313156","title":"2025上半年BD王者榜:国产创新药的国际突围","url":"https://stock-news.laohu8.com/highlight/detail?id=2550313156","media":"CPHI制药在线","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550313156?lang=zh_cn&edition=full","pubTime":"2025-07-09 17:45","pubTimestamp":1752054334,"startTime":"0","endTime":"0","summary":"二、技术出海先锋:和铂医药在2025年上半年的生物医药BD交易市场中,和铂医药同样表现得极为亮眼,成为了授权合作数量方面的佼佼者,凭借7项授权交易独占鳌头。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709190104a69f4bdc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709190104a69f4bdc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","02142","06978","01530","BK1574","688336","BK1583","688177","BK1161","02696"],"gpt_icon":0},{"id":"2549149845","title":"三生国健主力两日净流出6171.5万 短期股价或承压","url":"https://stock-news.laohu8.com/highlight/detail?id=2549149845","media":"智选洞察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549149845?lang=zh_cn&edition=full","pubTime":"2025-07-08 15:33","pubTimestamp":1751959990,"startTime":"0","endTime":"0","summary":"三生国健今日主力资金净流出2838.1万元,上一交易日主力净流出3333.4万元。连续两个交易日资金呈净流出状态,表明主力资金对当前股价走势持谨慎态度,短期内可能对股价形成一定压力。资金面与市场情绪共振引发短期波动三生国健近期主力资金呈现高频切换特征,截至7月3日,单日资金流向多次出现超5000万元级反转。动态市盈率45.15倍仍高于行业中枢,技术面压力与估值修正需求形成共振,进一步加剧股价波动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708154026a43d7a4e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708154026a43d7a4e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688336"],"gpt_icon":0},{"id":"2549561112","title":"被牛市遗忘的CXO,谁将凭“拐点基因”破局","url":"https://stock-news.laohu8.com/highlight/detail?id=2549561112","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549561112?lang=zh_cn&edition=full","pubTime":"2025-07-08 08:07","pubTimestamp":1751933234,"startTime":"0","endTime":"0","summary":"二级市场创新药的火热反衬出CXO的落寞。到了6月底,恒生港股通创新药指数宣布修订编制方案,剔除CXO企业,聚焦创新药核心公司。01和创新药脱钩的CXO二级市场股价走势反差的背后,是双方走到了不同的发展阶段。如今,二者明显分化的走势意味着CXO行业也走到了转型的关键节点。03业务的此消彼长业务结构性变化正在重塑CXO行业竞争格局。也就是说,临床CRO业务还将继续承压,当新开临床试验数量持续减少,内卷或更加严重。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708083555a43cb692&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708083555a43cb692&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03759","BK1161","688710","BK1574","BK1576","688336","06821","06978","06127","BK1141","BK1583","03347","09926","603127","02359","01801","BK1191"],"gpt_icon":0},{"id":"2549589875","title":"7月7日三生国健跌5.20%,交银医药创新股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2549589875","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549589875?lang=zh_cn&edition=full","pubTime":"2025-07-07 16:23","pubTimestamp":1751876633,"startTime":"0","endTime":"0","summary":"证券之星消息,7月7日三生国健跌5.20%,收盘报52.5元,换手率1.04%,成交量6.43万手,成交额3.44亿元。重仓三生国健的前十大公募基金请见下表:该股最近90天内共有6家机构给出评级,买入评级4家,增持评级2家;过去90天内机构目标均价为48.64。根据2025基金Q1季报公募基金重仓股数据,重仓该股的公募基金共10家,其中持有数量最多的公募基金为交银施罗德基金的交银医药创新股票A。该公募基金现任基金经理为楼慧源。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070700020821.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159938","BK1574","BK1161","09939","688336","BK1515"],"gpt_icon":0},{"id":"2549302426","title":"三生国健股价下跌5.00% 创近三个月新低 资金博弈与估值修正共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2549302426","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549302426?lang=zh_cn&edition=full","pubTime":"2025-07-07 13:21","pubTimestamp":1751865692,"startTime":"0","endTime":"0","summary":"三生国健股价大幅下跌,最新价52.61元/股,跌幅达5.00%。资金博弈与估值修正共振三生国健近期股价波动与资金面剧烈切换密切相关。生物制品板块资金分流压力显著,叠加6月25日上证指数单日下跌0.70%引发的避险情绪,部分资金选择兑现年初至今159.63%的涨幅收益。当前动态市盈率45.29倍仍高于行业中枢,技术面压力与资金轮动形成共振。但需关注集采政策影响及研发投入转化效率,近期股价从68.59元高点回调28.69%后,或进入震荡整固阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707132135a69a3769&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707132135a69a3769&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688336"],"gpt_icon":0},{"id":"2548047946","title":"生物制品行业盘中拉升,荣昌生物涨8.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2548047946","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548047946?lang=zh_cn&edition=full","pubTime":"2025-07-01 09:39","pubTimestamp":1751333947,"startTime":"0","endTime":"0","summary":"07月01日,生物制品行业盘中拉升,截至09点39分,生物制品行业整体指数上涨0.53%,报6182.770点。从个股上来看,该行业的成分股中,荣昌生物涨8.21%,甘李药业、百奥泰、三生国健涨幅居前。从资金上来看,截止发稿,生物制品行业主力净流入为4088.10万,其中荣昌生物受到资金热捧,主力净流入3206.13万;拉长时间线来看,该板块近20日主力资金净流入-33.02亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701093907a72736f8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701093907a72736f8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","LU1064131003.USD","688331","LU2488822045.USD","LU2148510915.USD","688336","LU1064130708.USD","688177"],"gpt_icon":0},{"id":"2548491042","title":"市场规模将增至108亿!国内一批药企在痛风药物领域展开激烈角逐","url":"https://stock-news.laohu8.com/highlight/detail?id=2548491042","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548491042?lang=zh_cn&edition=full","pubTime":"2025-07-01 09:19","pubTimestamp":1751332766,"startTime":"0","endTime":"0","summary":"据相关数据预测,到 2030 年,中国痛风药物市场规模将增长至 108 亿元,如此广阔的市场前景,吸引着国内众多药企纷纷积极布局,在痛风药物研发领域展开激烈角逐。痛风和高尿酸血症的高发,与现代人的生活方式和饮食习惯的改变密切相关。展望未来,随着国内药企在痛风药物研发上的持续投入和创新,中国痛风药物市场有望迎来新的发展格局。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025070109222097953d7c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025070109222097953d7c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600276","BK0239","688336","600867"],"gpt_icon":0},{"id":"2547015164","title":"中国创新药能否持续让世界买单?券商分析师最新观点","url":"https://stock-news.laohu8.com/highlight/detail?id=2547015164","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2547015164?lang=zh_cn&edition=full","pubTime":"2025-06-30 23:29","pubTimestamp":1751297340,"startTime":"0","endTime":"0","summary":"医药魔方统计,2025年1—5月,中国创新药企对外授权交易总金额已达455亿美元,超过2024年上半年的交易总额,创新药出海授权交易大爆发。亮眼数据的背后,是中国创新药整体水平的强势崛起。“中国创新药产业的研发、临床与生产能力,正处于与国际一线水平接轨的初始阶段。”由于BD数据不及预期,年内大涨明显的创新药企业荣昌生物股价近期大幅回调,从而带动创新药板块整体调整。华泰柏瑞恒生创新药ETF6月中旬以来一度单周下行超过8%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630233154a7267585&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630233154a7267585&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688321","600513","688163","688166","600216","603127","688068","688319","688202","688073","600535","600196","600682","603259","600521","600572","688317","06160","600420","603456","600645","688177","600422","688189","688506","600276","688235","600867","600380","603716","688356","688520","BK0239","600881","603590","601607","600789","603087","688198","603367","600267","688222","603707","603998","688181","159992","688331","600079","600851","600222","688091","600351","603567","688488","688505","600557","600200","600721","601089","ONC","600080","688336","600332","600774","688131","688278","600998","605199","600062","600056","688136","688513","603229","688117"],"gpt_icon":0},{"id":"2546786890","title":"三生国健06月26日遭主力抛售6530.1万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2546786890","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546786890?lang=zh_cn&edition=full","pubTime":"2025-06-26 15:21","pubTimestamp":1750922509,"startTime":"0","endTime":"0","summary":"06月26日, 三生国健股价跌1.78%,报收53.53元,成交金额3.7亿元,换手率1.12%,振幅3.91%,量比1.06。三生国健今日主力资金净流出6530.1万元,上一交易日主力净流出4143.3万元。|06月26日主力加仓幅度排名||#|股票简称|主力净额占比|#|欢瑞世纪|6.52%|#|华锋股份|6.02%|#|科创信息|5.98%|#|...|...|#4217|三生国健|-0.20%|三生国健所在的生物制品行业,今日主力净流出5.50亿元,行业排名23/124。净流出前三个股分别为荣昌生物、万泰生物、三生国健。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626171441a71e9637&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626171441a71e9637&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688336"],"gpt_icon":0},{"id":"2546219934","title":"三生国健:向激励对象授予115.70万股限制性股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2546219934","media":"格隆汇资讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546219934?lang=zh_cn&edition=full","pubTime":"2025-06-25 18:06","pubTimestamp":1750845995,"startTime":"0","endTime":"0","summary":"格隆汇6月25日丨三生国健(688336.SH)公布,公司以2025年6月25日为限制性股票的预留授予日,以11.83元/股的授予价格(调整后)向符合授予条件的43名激励对象授予115.70万股限制性股票。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250625180645978e46b2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250625180645978e46b2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688336","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1753849475709,"stockEarnings":[{"period":"1week","weight":0.0287},{"period":"1month","weight":0.0489},{"period":"3month","weight":0.9286},{"period":"6month","weight":1.5072},{"period":"1year","weight":2.1078},{"period":"ytd","weight":1.6183}],"compareEarnings":[{"period":"1week","weight":0.0078},{"period":"1month","weight":0.0542},{"period":"3month","weight":0.1008},{"period":"6month","weight":0.1105},{"period":"1year","weight":0.2482},{"period":"ytd","weight":0.077}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"三生国健药业(上海)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"10791人(较上一季度增加0.04%)","perCapita":"57157股","listingDate":"2020-07-22","address":"上海市浦东新区中国(上海)自由贸易试验区李冰路399号","registeredCapital":"61678万元","survey":" 三生国健药业(上海)股份有限公司的主营业务是抗体药物的研发、生产和销售。公司的主要产品是益赛普、赛普汀、健尼哌。公司是“免疫与炎症全国重点实验室”依托单位、拥有抗体药物国家工程研究中心、国家企业技术中心、上海市抗体技术创新中心、上海抗体工程技术研究中心等国家级和上海市级高新技术平台,承担过国家重大新药创制、“863”计划、国家发改委及上海市重大项目及各部委课题百余项,多次获得上海市级和浦东新区科学技术奖。","listedPrice":28.18},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"三生国健(688336)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供三生国健(688336)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"三生国健,688336,三生国健股票,三生国健股票老虎,三生国健股票老虎国际,三生国健行情,三生国健股票行情,三生国健股价,三生国健股市,三生国健股票价格,三生国健股票交易,三生国健股票购买,三生国健股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"三生国健(688336)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供三生国健(688336)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}